Dr Reddy's Receives US FDA Tentative Approval for Generic HIV Prevention Drug
Dr Reddy's Laboratories has received tentative US FDA approval for its generic injectable HIV prevention drug lenacapavir, administered twice yearly. This approval, under the FDA's PEPFAR program, enables supply across 120 low- and middle-income countries under a voluntary license from Gilead Sciences. Priced at $40 per person annually, initial supplies are expected by late 2026, with broader rollout in 2027. Partnerships with Unitaid, Wits RHI, and CHAI support regulatory and access efforts, aiming to expand affordable HIV prevention globally.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (73/100). Lens Score 50/100.
Outlets measured: thehindu, news18, moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 2 Nov, 03:39 pm. Other outlets followed.